BR112015015713A2 - pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo - Google Patents

pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo

Info

Publication number
BR112015015713A2
BR112015015713A2 BR112015015713A BR112015015713A BR112015015713A2 BR 112015015713 A2 BR112015015713 A2 BR 112015015713A2 BR 112015015713 A BR112015015713 A BR 112015015713A BR 112015015713 A BR112015015713 A BR 112015015713A BR 112015015713 A2 BR112015015713 A2 BR 112015015713A2
Authority
BR
Brazil
Prior art keywords
sustained release
preconcentrate
pharmacologically active
pharmaceutical composition
active anionic
Prior art date
Application number
BR112015015713A
Other languages
English (en)
Inventor
Jeong Park Eun
Seong Ko Ki
Hyo Ki Min
Phil Yoon Sang
Hyun Park So
Joon Hong Sung
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of BR112015015713A2 publication Critical patent/BR112015015713A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo a presente invenção se refere a um pré-concentrado lipídico de liberação sustentada, compreendendo: a) pelo menos um formador de cristal líquido; b) pelo menos um fosfolipídio; c) pelo menos um endurecedor de cristal líquido; e d) pelo menos um sal metálico bi ou polivalente, em que o pré-concentrado de liberação sustentada existe como uma fase de lipídio líquido na ausência de fluido aquoso e se forma em um cristal líquido após exposição a fluidos aquosos. o pré-concentrado lipídico de liberação sustentada é configurado para melhorar a liberação controlada de substâncias ativas farmacologicamente aniônicas através de interação iónica entre o sal metálico bi ou polivalente e a substâncias aniônicas farmacologicamente ativas.
BR112015015713A 2012-12-28 2013-12-27 pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo BR112015015713A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120157582A KR101586790B1 (ko) 2012-12-28 2012-12-28 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
PCT/KR2013/012265 WO2014104788A1 (en) 2012-12-28 2013-12-27 Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BR112015015713A2 true BR112015015713A2 (pt) 2017-07-11

Family

ID=51021734

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015713A BR112015015713A2 (pt) 2012-12-28 2013-12-27 pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo

Country Status (13)

Country Link
US (1) US20150290322A1 (pt)
EP (1) EP2938333A4 (pt)
JP (1) JP6166382B2 (pt)
KR (1) KR101586790B1 (pt)
CN (1) CN105188681A (pt)
AU (1) AU2013371098B2 (pt)
BR (1) BR112015015713A2 (pt)
CA (1) CA2888801C (pt)
MX (1) MX2015008402A (pt)
NZ (1) NZ710471A (pt)
PH (1) PH12015501554A1 (pt)
RU (1) RU2632436C2 (pt)
WO (1) WO2014104788A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
HUE033790T2 (en) 2013-01-31 2017-12-28 Chong Kun Dang Pharmaceutical Corp CETP inhibitor biaryl or heterocyclic biaryl substituted cyclohexene derivatives
KR101809908B1 (ko) 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
DK3512495T3 (da) * 2016-09-15 2022-12-05 Camurus Ab Formuleringer af prostacyklinanaloger
KR102186704B1 (ko) * 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN113018254A (zh) * 2021-04-13 2021-06-25 安徽中医药大学 一种用于治疗原发性痛经的布洛芬液晶凝胶经皮制剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3706036A1 (de) * 1987-02-25 1988-09-08 Basf Ag Polyacetale, verfahren zu deren herstellung aus dialdehyden und polyolcarbonsaeuren und verwendung der polyacetale
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
TR199901008T1 (xx) * 1997-09-09 2000-02-21 Select Release, L.C. Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
TWI241915B (en) 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
WO2003032947A2 (en) * 2001-09-06 2003-04-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1682091B1 (en) * 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
SE526127C2 (sv) 2003-11-14 2005-07-12 Nilar Int Ab En packning, ett bipolärt batteri och en metod för tillverkning av ett bipolärt batteri med en sådan packning
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
JP5171262B2 (ja) 2005-01-14 2013-03-27 カムルス エービー ソマトスタチン類似体製剤
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
US20100129456A1 (en) * 2007-05-14 2010-05-27 Ltt Bio-Pharma Co., Ltd. Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
AU2010227549B2 (en) 2009-03-25 2014-02-27 Novartis Ag Pharmaceutical composition containing a drug and siRNA
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
MX2015008402A (es) 2016-02-16
WO2014104788A1 (en) 2014-07-03
KR20140086740A (ko) 2014-07-08
JP6166382B2 (ja) 2017-07-19
EP2938333A1 (en) 2015-11-04
RU2015131109A (ru) 2017-02-03
AU2013371098B2 (en) 2016-11-17
PH12015501554A1 (en) 2015-09-21
AU2013371098A1 (en) 2015-08-13
US20150290322A1 (en) 2015-10-15
RU2632436C2 (ru) 2017-10-04
KR101586790B1 (ko) 2016-01-19
CN105188681A (zh) 2015-12-23
NZ710471A (en) 2016-04-29
EP2938333A4 (en) 2016-06-15
JP2016504352A (ja) 2016-02-12
CA2888801C (en) 2017-11-28
CA2888801A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
BR112015015707A2 (pt) pré-concentrado de lipídio de liberação prolongada de substância ativa farmacologicamente catiônica e composição farmacêutica compreendendo a mesma
BR112015015713A2 (pt) pré-concentrado lipídico de liberação sustentada de substâncias aniônicas farmacologicamente ativas e composição farmacêutica compreendendo o mesmo
CL2015002708A1 (es) Compuestos heterocíclicos y sus usos.
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CR20150629A (es) Compuestos químicos
BR112016009874A2 (pt) Dispositivos de liberação de fármaco, e composições farmacêuticas e usos
BR112015007659A2 (pt) mecanismos químicos e métodos para o uso dos mesmos, especialmente na injeção de fluidos altamente viscosos
CL2013000815A1 (es) Composicion farmaceutica liquida de adm inistracion parenteral que comprende dexmedetomidina o una sal de la misma en una concentracion de 0,005 a 50 µg/ml y adicionalmente comprende cloruro de sodio en una concentracion de 0,01 a 2 % en peso, dispuesta dentro de un contenedor de vidrio sellado.
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
GT201300313A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BR112014012522A2 (pt) método para encher um reservatório, reservatório e conjunto para encher um reservatório
BR112015021332A2 (pt) sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
ECSP15050386A (es) FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112014017834A8 (pt) Sistema de distribuição de fármacos
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
BR112014023250A8 (pt) Dispositivo e método de controle de exibição, e, mídia legível por computador
ES2722926T3 (es) Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas
BR112015005268A2 (pt) seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso
BR112015014078A2 (pt) composição farmacêutica oftalmológica tópica que contém regorefenib
BR112015014341A2 (pt) pipeta de dosagem
BR112017023693A2 (pt) composição cosmética ou dermatológica na forma de uma nanoemulsão de óleo-em-água, uso cosmético da composição e uso da composição
FR2991175B1 (fr) Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2546 DE 22-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.